Sanofi (SNY) Q3 2024 Earnings Call Transcript
Sanofi (NASDAQ:SNY ) Q3 2024 Earnings Conference Call October 25, 2024 8:00 AM ET Company Participants Thomas Kudsk - Head of Investor Relations Paul Hudson - Chief Executive Officer Francois Roger - Executive Vice President, Chief Financial Officer Houman Ashrafian - Executive Vice President, Head of Research and Development Thomas Triomphe - Executive Vice President, Vaccines Brian Foard - Executive Vice President, Head of Specialty Care Brendan O'Callaghan - Executive Vice President, Manufacturing and Supply Roy Papatheodorou - Executive Vice President, General Counsel Conference Call Participants Richard Vosser - JPMorgan Emily Field - Barclays Graham Parry - BofA Seamus Fernandez - Guggenheim Jo Walton - UBS Peter Welford - Jefferies Luisa Hector - Berenberg Thibault Boutherin - Morgan Stanley Simon Baker - Redburn Steve Scala - TD Cowen David Risinger - Leerink Richard Parkes - BNP Exane Rajesh Kumar - HSBC Eric Berrigaud - Stifel Florent Cespedes - Bernstein Thomas Kudsk Welcome to the Q3 2024 Conference Call for Investors and Analysts. As usual, you can find the slides on sanofi.com.
Sanofi Q3 Earnings Beat, Dupixent, New Drugs, Vaccines Drive Sales
SNY posts strong third-quarter results, beating estimates for both earnings and sales. Shares rise in pre-market.
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat
Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales.
Sanofi CEO Paul Hudson on Q3 results: The modernization effort is starting to pay off
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, drug pipeline outlook, the company's Dupixent drug, and more.
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
On Friday, Sanofi SA SNY reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), up 14.4% year-over-year and 19.9% in constant currency.
Sanofi Q3 earnings beat market view, boosted by vaccine sales
French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by earlier-than-anticipated sales of seasonal vaccines.
Sanofi Negotiating Exclusively With CD&R for Opella 50% Stake Sale
SNY is negotiating with CD&R to sell a 50% stake in its consumer healthcare business, Opella.
French govt set to take stake in Sanofi unit after PE sale
France is reportedly set to acquire a small stake in Sanofi SA's (ADR) (NYSE:SNY) consumer healthcare unit as the pharmaceutical company proceeds with a €16 billion deal to sell half of the business to US private equity firm Clayton, Dubilier & Rice (CD&R), despite political opposition. Sanofi entered exclusive talks with CD&R to sell 50% of Opella, the division behind well-known products like Doliprane, a popular painkiller in France.
Sanofi enters exclusive talks with CD&R for Opella sale
Sanofi said on Monday it had entered exclusive negotiations for the sale of a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R).
Sanofi to sell 51% stake in Opella to CD&R, 1% to BPI
France will take a stake in Sanofi 's Opella through the Public Investment Bank (BPI), finance minister Antoine Armand said on Sunday, confirming an information from Le Figaro newspaper that U.S. private equity firm Clayton Dubilier & Rice (CD&R) is to take a 51% stake in the company that makes of one of France's most-sold painkillers, Doliprane.
SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies
Sanofi inks an agreement with Orano Med to develop next-generation radioligand medicines to treat rare cancers.
Workers at Sanofi to strike to protest consumer health unit sale, union official says
France's CGT and CFDT unions have called on workers at pharma company Sanofi to strike from Thursday to show their protest against a planned sale of a controlling stake in the firm's consumer health arm, a union official said on Wednesday.
